Lumicera Secures Purchase Agreement for Stelara® Biosimilar, Delivering Major Cost Savings [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
MADISON, Wis., March 13, 2025 BUSINESS WIRE Lumicera Health Services announced today it has secured a purchase agreement with Anda, Inc., an independent wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., for a lower-priced biosimilar version of Stelara ® (ustekinumab). Stelara ranks as one of the most expensive prescription drugs on the market . Under this agreement, Lumicera's discounted net acquisition cost for the unbranded biosimilar (ustekinumab-aekn) is estimated to generate $120 million in annualized savings for clients. These savings will be accessed immediately through Lumicera's pass-through, acquisition cost-plus model, not delayed through a rebated model. Plan sponsors will save between $112,000 an
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry PharmaPR Newswire
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target lowered by analysts at Bank of America Co. from $23.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- United States Lidocaine Patches Market Report 2024 with Long-term Outlook, Competitive Landscape of Amneal, Endo, Hisamitsu, Medline, Scilex, Sparsha, Teikoku, Teva, Viatris, and YARAL [Yahoo! Finance]Yahoo! Finance
- Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March [Yahoo! Finance]Yahoo! Finance
TEVA
Earnings
- 1/29/25 - Beat
TEVA
Sec Filings
- 3/7/25 - Form 4
- 3/7/25 - Form 4
- 3/7/25 - Form 4
- TEVA's page on the SEC website